L-glutamine/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
No detected effect on all-cause mortality
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×4“The mortality rate was insignificantly different between glutamine group and placebo group (22.7% vs. 36.4% respectively, p-value = 0.509) as presented in Table 4 and.”
Quoted verbatim from Ameliorative Potential of L-Alanyl L-Glutamine Dipeptide in Colon Cancer Patients Receiving Modified FOLFOX-6 Regarding the Incidence of Diarrhea, the Treatment Response, and Patients' Survival: A Randomized Controlled Trial.. - Study
- RCT
- Participants
- 44
- Dose
- 20 gm/100 mL intravenous N(2)-L-Alanyl-L-Glutamine Dipeptide (Dipeptiven) on the day 1-2 regimen every 2 weeks
- Population
- Stage II and III colon cancer patients, both arms receiving identical mFOLFOX-6 chemotherapy, randomised to intravenous L-alanyl L-glutamine dipeptide or placebo; mortality over the trial follow-up
Ameliorative Potential of L-Alanyl L-Glutamine Dipeptide in Colon Cancer Patients Receiving Modified FOLFOX-6 Regarding the Incidence of Diarrhea, the Treatment Response, and Patients' Survival: A Randomized Controlled Trial.2022PMID:35334570Permalink
Keep reading
- Everything the graph holds on L-glutamine
- Every compound studied against All-cause mortality
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M0ZG9TJSAG5KCT0X6EQKYHHP